TG-hAPOC3 Mouse
Product Name
TG-hAPOC3 Mouse
Product ID
C001588
Strain Name
C57BL/6NCya-Tg(hAPOC3)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “TG-hAPOC3 Mouse (Catalog C001588) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
APOC3
Gene Alias
Apo-C3, ApoC-3, APOCIII
NCBI ID
Chromosome
Chr 11 (Human)
MGI ID
Datasheet
Strain Description
Apolipoprotein C-III (ApoC-III), encoded by the APOC3 gene, is a 79-amino acid glycoprotein primarily synthesized in the liver, with minor production in the intestine. ApoC-III is a key component of triglyceride-rich lipoproteins (TRLs), including chylomicrons and very low-density lipoprotein (VLDL). Its primary functions include inhibiting lipoprotein lipase (LPL)-mediated hydrolysis of triglycerides within TRLs and modulating hepatic uptake of TRL remnants, thereby elevating plasma triglyceride levels. Consequently, ApoC-III is crucial in regulating plasma triglyceride levels [1-2]. Elevated APOC3 expression leads to increased ApoC-III levels, which is associated with hypertriglyceridemia (a risk factor for cardiovascular disease) and conditions such as familial hypertriglyceridemia, metabolic syndrome, and type 2 diabetes. Therefore, targeting the reduction of APOC3 expression or blocking its protein function offers a therapeutic avenue for hypertriglyceridemia and mitigating cardiovascular disease risk [3].
The TG-hAPOC3 mouse is a humanized model generated by integrating the human APOC3 gene sequence, encompassing the upstream and downstream untranslated regions (UTRs), into the mouse genome, enabling the expression of human ApoC-III protein in vivo. This model is valuable for developing therapeutics targeting human APOC3, such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), for the treatment of hypertriglyceridemia.
Reference
Borén J, Packard CJ, Taskinen MR. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. Front Endocrinol (Lausanne). 2020 Jul 28;11:474.
Ramms B, Gordts PLSM. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol. 2018 Jun;29(3):171-179.
Chebli J, Larouche M, Gaudet D. APOC3 siRNA and ASO therapy for dyslipidemia. Curr Opin Endocrinol Diabetes Obes. 2024 Apr 1;31(2):70-77.
Strain Strategy
The human APOC3 gene sequence, including the 5'UTR and 3'UTR sequences, was integrated into the mouse genome using transgenic (TG) technology.
Figure 1. Diagram of the gene editing strategy for the generation of TG-hAPOC3 mice.
Application Area
Development, screening, and preclinical efficacy evaluation of therapeutics targeting human APOC3;
Investigation of the pathogenic mechanisms and therapeutic strategies for hypertriglyceridemia (HTG).
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
